Literature DB >> 8484270

[Repeated perioperative administration of fructose and sorbitol in a female patient with hereditary fructose intolerance [HFI)].

M Sachs1, F Asskali, H Förster, A Encke.   

Abstract

The present paper reports on an adult female patient whose hereditary fructose intolerance (HFI) was at first not diagnosed and who, within the space of 2 years after repeated elective surgery and the perioperative administration of fructose and sorbitol, developed "hepatic and renal failure of unclear origin." At a later stage we were able to establish the diagnosis of HFI by means of a fructose tolerance test in both she and her brother, for whom intolerance to fruit and desserts had been known since early childhood. In addition, literature references to fatalities following the parenteral application of fructose and sorbitol were analyzed. During the course of fructose infusion in both the patient and her brother with HFI, the following metabolic changes were noted: hypoglycemia, elevated rise in the blood fructose concentration, hyperlactacidemia, elevated rise in the blood fructose concentration, hyperlactacidemia, and hyperammonemia. These metabolic changes proved to be reversible after discontinuing the fructose infusion. Analysis of the literature on the fatalities following parenteral fructose administration established that fruit and dessert intolerance was known for all collated patients with HFI, and that, clearly, no regular metabolic tests had been conducted.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484270     DOI: 10.1007/bf01610085

Source DB:  PubMed          Journal:  Z Ernahrungswiss        ISSN: 0044-264X


  16 in total

1.  [Enzymatic determination of glucose and fructose simultaneously].

Authors:  F H SCHMIDT
Journal:  Klin Wochenschr       Date:  1961-12-01

2.  [Fatal consequences of fructose infusion in undiagnosed fructose intolerance].

Authors:  M Rey; R Behrens; G Zeilinger
Journal:  Dtsch Med Wochenschr       Date:  1988-06-10       Impact factor: 0.628

3.  [Hereditary fructose intolerance].

Authors:  L Sestoft
Journal:  Ugeskr Laeger       Date:  1974-03-04

4.  [Fatal liver dystrophy in 3 siblings with hereditary fructose intolerance after long-lasting infusion with sorbitol solutions].

Authors:  W Heine; H Schill; D Tessmann; H Kupatz
Journal:  Dtsch Gesundheitsw       Date:  1969-12-04

5.  [Five cases of lactic acidosis (author's transl)].

Authors:  D Balogh; J M Hackl
Journal:  Wien Klin Wochenschr       Date:  1978-10-13       Impact factor: 1.704

6.  [Acute liver and kidney failure following sorbitol infusion in a 28-year-old patient with undiagnosed fructose intolerance].

Authors:  S Locher
Journal:  Anasth Intensivther Notfallmed       Date:  1987-08

7.  [Fructose and sorbitol as energy-supplying substrates for parenteral nutrition].

Authors:  H Förster
Journal:  Infusionsther Klin Ernahr       Date:  1987-06

8.  [Metabolic changes and infusion therapy in ileus].

Authors:  M Sachs; F Asskali; B Ziegler; H Bockhorn; H Förster; E Ungeheuer
Journal:  Chirurg       Date:  1989-12       Impact factor: 0.955

9.  [Infusion-associated kidney and liver failure in undiagnosed hereditary fructose intolerance].

Authors:  D E Müller-Wiefel; B Steinmann; M Holm-Hadulla; L Wille; K Schärer; R Gitzelmann
Journal:  Dtsch Med Wochenschr       Date:  1983-06-24       Impact factor: 0.628

10.  [Postoperative fructose infusion in a case of presumed hereditary fructose intolerance (author's transl)].

Authors:  J M Hackl; D Balogh; F Kunz; E Dworzak; B Puschendorf; A Decristoforo; F Maier
Journal:  Wien Klin Wochenschr       Date:  1978-03-31       Impact factor: 1.704

View more
  1 in total

1.  Ketohexokinase C blockade ameliorates fructose-induced metabolic dysfunction in fructose-sensitive mice.

Authors:  Miguel A Lanaspa; Ana Andres-Hernando; David J Orlicky; Christina Cicerchi; Cholsoon Jang; Nanxing Li; Tamara Milagres; Masanari Kuwabara; Michael F Wempe; Joshua D Rabinowitz; Richard J Johnson; Dean R Tolan
Journal:  J Clin Invest       Date:  2018-04-23       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.